glp-1 drugs key developments 2025 2.0: Where the Next Wave of Value Will Be Created GLP‑1 Weight Loss Providers Roundup:

The accumulated evidence from CVOTs has not only informed clinical practice guidelines but has also empowered healthcare providers with a valuable therapeutic option for T2D patients who have high cardiovascular risk

FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

"Without this coordination, there's a risk employees receive medication without addressing the broader behavioral health needs that drive alcohol-related absenteeism, healthcare costs and safety concerns." Read more: Based on the people she's spoken with at Eleanor Health, Harrison said that most clinicians are excited about "At the same time, most clinicians view GLP-1s as a potential complement, not a replacement, for established addiction care," she said

The half-life of GLP-1(7-37) in plasma is 1 to 2 min, necessitating the use of an infusion to deliver it in sufficient amounts